Infectious disease
The AMR Pipeline Is Too Thin for the Threat Ahead
The 2026 AMR Benchmark shows that industry efforts are still being outpaced by drug resistance, with antimicrobial innovation, access, stewardship and manufacturing all under pressure.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.